Creative Planning
ADVM

Creative Planning’s Adverum Biotechnologies ADVM Stock Holding History

Creative Planning’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,100
Closed -$242K – 1864
2019
Q4 		$242K Hold
2,100
– – ﹤0.01% 1530
2019
Q3 		$114K Buy
2,100
+100
+5% +$11.3K ﹤0.01% 1697
2019
Q2 		$238K Hold
2,000
– – ﹤0.01% 1505
2019
Q1 		$105K Hold
2,000
– – ﹤0.01% 1701
2018
Q4 		$63K Sell
2,000
-307
-13% -$12.5K ﹤0.01% 1684
2018
Q3 		$140K Buy
2,307
+20
+0.9% +$1.12K ﹤0.01% 1739
2018
Q2 		$121K Buy
2,287
+994
+77% +$59.8K ﹤0.01% 1737
2018
Q1 		$75K Buy
+1,293
New +$80.5K ﹤0.01% 1782
2015
Q4 		– Sell
-500
Closed -$41K – 4384
2015
Q3 		$41K Buy
+500
New +$63.9K ﹤0.01% 2168

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Creative Planning's ADVM Position: Q1 2020 in Review

Creative Planning sold out of Adverum Biotechnologies (ADVM) in Q1 2020, closing a stake of 2,100 shares — an estimated $242K sold.

Creative Planning first reported a position in ADVM in Q3 2015 and held it in 9 quarters. The position peaked at $242K in Q4 2019. 126 funds tracked by Wall St. Rank hold ADVM as of Q1 2020.

  • Creative Planning reported no remaining Adverum Biotechnologies position as of Q1 2020 after selling out during the quarter.
  • Creative Planning sold 2,100 Adverum Biotechnologies shares in Q1 2020, an estimated $242K.
  • Creative Planning first reported a position in Adverum Biotechnologies in Q3 2015 and held it in 9 quarters.
  • Creative Planning's Adverum Biotechnologies position peaked at $242K in Q4 2019.
  • 126 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2020.

Based on Creative Planning's 13F filing for Q1 2020, filed 5 May 2020.